title: Acquired resistance to monepantel in C. elegans: What about parasitic nematodes?
abstract: In 2008, Novartis Animal Health developed a new class of anthelmintics, the amino-acetonitrile derivatives (AAD) of which monepantel is the most prominent compound. Monepantel was designed for the treatment of sheep against the parasitic nematode Haemonchus contortus. Because monepantel acts through a different mechanism, it is effective against nematodes that have acquired resistance to long-standing anthelmintics. In order to benefit from a maximum lifespan and efficacy of this new compound, the mode of action of monepantel needs to be understood. Studies on the model nematode Caenorhabditis elegans led to the identification of at least one target of monepantel: the monovalent cation channel ACR-23. Here we comment on the effects of monepantel on C. elegans and on the development of resistant parasitic nematode strains.
authors.affiliation: Department of Biology; University of Fribourg ; Fribourg, Switzerland.
authors.forename: Michael Forbiteh
authors.initials: MF
authors.lastname: Fru
authors.affiliation: Department of Biology; University of Fribourg ; Fribourg, Switzerland.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Puoti
keywords: C. elegans; acr-23; anthelmintic; monepantel; motility; parasite